We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Anastomotic Leak in Gastrointestinal (GI) Anastomosis With the Application of Tisseal in the Anastomotic Line

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by Hospital General Universitario Gregorio Marañon.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01306851
First Posted: March 2, 2011
Last Update Posted: March 2, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hospital General Universitario Gregorio Marañon
  Purpose

The anastomotic leak is one of the most feared complications in abdominal surgery. Certain control methods have been described but the incidence of that complication remains high and is the first cause of mortality in operations where gut anastomosis are performed.

With the aim to prove that the use of fibrin glue in the gut anastomosis can improve gut cicatrization, the investigators started the recruitment of patients to that clinical trial in 2007 with the study hypothesis that patients with a gut anastomosis where fibrin glue was used, had less anastomotic leaks than that where the fibrin glue was not used.

The investigators have calculated the number of patients necessaries to have statistical significant differences in 200 patients with a rate anastomotic leak expected to be higher than 10%.

The study include all the patients that usually arrive to our surgery department and that are expected to have a high risk gut anastomosis: rectal anastomosis, GI anastomosis in the obese patient, small bowel anastomosis in the obstructed one and esophageal anastomosis.

The study is randomized, simple blind where the patient does not know if they are in the fibrin glue group or not, and prospectively analyzed. All the clinical and laboratory or radiographic finds relative to the occurrence of an anastomotic leak are recorded.


Condition Intervention Phase
Anastomotic Leak Drug: Fibrin glue Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Multicenter, Randomized, Controlled, Single Blinded, Phase IV Study Comparing 2 Parallel Groups in the Evaluation of the Prevention of Anastomotic Leaks in GI High Risk Anastomosis, With or Without the Application of Fibrin Glue in the Anastomotic Line

Further study details as provided by Hospital General Universitario Gregorio Marañon:

Primary Outcome Measures:
  • Occurence of anastomotic leak [ Time Frame: 6 months ]
    The occurence of anastomotic leak in the 6 months after the surgery is the most important factor to determine if fibrin glue is helpful in the prevention of that complicacion.


Secondary Outcome Measures:
  • Evidence of infectious collections in the anastomotic area [ Time Frame: 3 months ]

Estimated Enrollment: 200
Study Start Date: June 2007
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fibrin glue Drug: Fibrin glue
In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing GI surgery where a high risk anastomosis is preview to be done

Exclusion Criteria:

  • Haemodynamic instability
  • Advanced oncologic disease
  • Proteins below 4 gr/ml
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01306851


Contacts
Contact: Lago Jesus, MD +34618302092 jesus.lago@salud.madrid.org

Locations
Spain
Hospital General Universitario Gregorio Marañon Recruiting
Madrid, Spain, 28007
Contact: Lago Jesus, MD    +34618302092    jesus.lago@salud.madrid.org   
Principal Investigator: Lago Jesus, MD         
Sponsors and Collaborators
Hospital General Universitario Gregorio Marañon
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jesús Lago Oliver, Hospital General Universitario "Gregorio Marañón"
ClinicalTrials.gov Identifier: NCT01306851     History of Changes
Other Study ID Numbers: PROTTISUCOL-001
First Submitted: March 1, 2011
First Posted: March 2, 2011
Last Update Posted: March 2, 2011
Last Verified: May 2007

Keywords provided by Hospital General Universitario Gregorio Marañon:
fibrin glue
anastomotic leak
gastrointestinal high risk anastomosis

Additional relevant MeSH terms:
Anastomotic Leak
Postoperative Complications
Pathologic Processes
Fibrin Tissue Adhesive
Hemostatics
Coagulants


To Top